Articles On Amplia Therapeutics (ASX:ATX)

Pharmaceutical company Amplia Therapeutics (ATX) enters into a trading halt as it plans an upcoming capital raise It is not known how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will...

The company has also entered a trading halt as it undertakes a capital-raising process. The halt is in place until Monday, November 8, or when an announcement is released to the market.

Amplia Therapeutics is raising $12.4 million to fund human clinical trials and drug manufacturing for its drug candidate designed to slow cancer progression.

Amplia Therapeutics (ASX: ATX) has appointed experienced spearhead of pancreatic cancer treatments Dr José Iglesias as clinical advisor to assist with development of its cancer and fibroid drugs. The company pointed out that Dr Iglesias was...

José Iglesias MD will join the ATX team as a clinical advisor, providing more than 30 years of experience in the pharmaceutical industry.

Many successful investors in healthcare have made money by patiently backing companies that are quietly and strategically trying to solve big problems, like Australian biotech company Amplia Therapeutics (Amplia, ASX:ATX).

Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhesion kinase (FAK) inhibitors for cancer...

The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.

George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years. 

New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned Phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prio...

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.

Amplia Therapeutics (ASX:ATX), which is developing new drugs for the treatment of cancer and fibrosis, has announced the publication of a paper from the Garvan Institute of Medical Research.

Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.

The ASX was set for another negative day if futures and Wall Street’s drop were any guide — but even with a bad start, Australia’s bourse finished in the green. The ASX 200 fell as much as 0.50% in the first few minutes of trade but closed...

It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases.

The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.

Highlights The ASX 200 fell 18.7 points or 0.25% to 7,418.6 in the opening session, while the ASX All ordinaries index was 0.24% down at 7,722.1.   The market breadth is extremely weak so far today, with 10 out of the 11 sectors trad...

The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo...

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a Phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced pancreatic cancer. The design is based...

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

The ASX 200 finished in the red today, as the big end of town played second fiddle to the microcap Emerging Companies index which posted a solid ~0.7% gain. Mining stocks dragged on the broader index, as BHP (ASX:BHP) traded ex-dividend (it...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis (IPF) patients. This work is being suppo...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis. The results confirmed the company’s prelimi...

Wall Street, European stocks rebound on the dip All three US benchmarks rallied overnight, along with the European sharemarkets as investors bought the dip. The Dow Jones rose 1.62%, S&P 500 by 1.52%, while the Nasdaq rose by 1.57%. The...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat patients with pancreatic cancer. The Melbo...

Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

The Amplia Therapeutics Ltd (ASX: ATX) share price is one of the best performers on the ASX today. This comes after the pharmaceutical company announced positive news in trials to improve pancreatic cancer survival. At one point in intrada...

Summary Amplia Therapeutics has received promising data from its Focal Adhesion Kinase inhibitor in the treatment of cancer. Spectur expects to post a record revenue of approximately AU$1.8 million in Q4. Douugh has formed a strategic...

Biotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data. The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK). FAK is a protein that is over-expressed...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Amplia Therapeutics (ASX:ATX) says it has received new data from its collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research in Sydney.

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr...

After gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The ASX 200 closed at 7,029 points, which was 0.04 per cent higher than Friday. Small caps had a worse day – the ASX Emerging Companies Index clos...

Small caps have declined for the fourth time in the past five days — but still finished April with their strongest performance in six months. The Small Ordinaries index gained 4.83 per cent in April despite declining 0.96 per cent this week...

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Summary Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH. The positive data from the animal study is anticipated to support the future development and part...